IN2014CH00247A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00247A
IN2014CH00247A IN247CH2014A IN2014CH00247A IN 2014CH00247 A IN2014CH00247 A IN 2014CH00247A IN 247CH2014 A IN247CH2014 A IN 247CH2014A IN 2014CH00247 A IN2014CH00247 A IN 2014CH00247A
Authority
IN
India
Prior art keywords
novel
dolutegravir
preparation
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
Inventor
Chava Satyanarayana
Ramanjaneyulu Gorantla Seeta
Lakshmi Narasimha Rao Dammalapati Venkata
Bushan Kotala Mani
Aduri Ravindra
Original Assignee
Laurus Labs Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Private Ltd filed Critical Laurus Labs Private Ltd
Priority to IN247CH2014 priority Critical patent/IN2014CH00247A/en
Priority to US15/113,080 priority patent/US9856271B2/en
Priority to ES15740288T priority patent/ES2770050T3/en
Priority to EP15740288.4A priority patent/EP3096763B1/en
Priority to PCT/IB2015/000048 priority patent/WO2015110897A2/en
Priority to PCT/IN2015/000040 priority patent/WO2015111080A2/en
Publication of IN2014CH00247A publication Critical patent/IN2014CH00247A/en
Priority to US15/809,151 priority patent/US10301321B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof using novel intermediates.
IN247CH2014 2014-01-21 2015-01-20 IN2014CH00247A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IN247CH2014 IN2014CH00247A (en) 2014-01-21 2015-01-20
US15/113,080 US9856271B2 (en) 2014-01-21 2015-01-20 Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
ES15740288T ES2770050T3 (en) 2014-01-21 2015-01-20 New procedure for the preparation of dolutegravir and its pharmaceutically acceptable salts
EP15740288.4A EP3096763B1 (en) 2014-01-21 2015-01-20 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
PCT/IB2015/000048 WO2015110897A2 (en) 2014-01-21 2015-01-20 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
PCT/IN2015/000040 WO2015111080A2 (en) 2014-01-21 2015-01-21 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
US15/809,151 US10301321B2 (en) 2014-01-21 2017-11-10 Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN247CH2014 IN2014CH00247A (en) 2014-01-21 2015-01-20

Publications (1)

Publication Number Publication Date
IN2014CH00247A true IN2014CH00247A (en) 2015-08-14

Family

ID=53682060

Family Applications (1)

Application Number Title Priority Date Filing Date
IN247CH2014 IN2014CH00247A (en) 2014-01-21 2015-01-20

Country Status (5)

Country Link
US (2) US9856271B2 (en)
EP (1) EP3096763B1 (en)
ES (1) ES2770050T3 (en)
IN (1) IN2014CH00247A (en)
WO (2) WO2015110897A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030003B1 (en) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Polycyclic carbamoylpyridone compound and pharmaceutical use thereof for treating hiv infection
NO2865735T3 (en) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (en) 2014-06-20 2018-06-23
CZ201599A3 (en) * 2015-02-13 2016-08-24 Zentiva, K.S. Solid forms of dolutegravir salts and process for preparing thereof
ES2742249T3 (en) * 2015-12-21 2020-02-13 Lupin Ltd Process for the preparation of HIV integrase inhibitors
CN105699509B (en) * 2016-01-23 2018-08-31 河北科技大学 A kind of method for separating and detecting of 3- amino butanols enantiomter
CN106565747A (en) * 2016-11-10 2017-04-19 顾世海 Novel method for preparing dolutegravir
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited New polymorphs of dolutegravir sodium
JP6924839B2 (en) 2017-10-06 2021-08-25 塩野義製薬株式会社 A stereoselective method for producing a substituted polycyclic pyridone derivative
CN107935881B (en) * 2017-12-11 2020-06-26 浙江朗华制药有限公司 Preparation method of N- [ (2, 4-difluorophenyl) methyl ] -4-methoxy-3-oxobutanamide
US20210380602A1 (en) * 2018-10-19 2021-12-09 Virginia Commonwealth University Novel pyrrole and pyridone derivatives and uses thereof
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN110294705A (en) * 2019-07-25 2019-10-01 浙江沙星科技有限公司 A kind of synthetic method of Du Lutewei key intermediate
CN111620891B (en) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 Polyteplavir key intermediate solvate polymorph and preparation method and application thereof
JP7685522B2 (en) 2020-11-17 2025-05-29 塩野義製薬株式会社 Novel acridinium salt and method for producing same
CN116496297B (en) * 2023-03-24 2025-03-11 天津大学 A kind of dolutegravir oxalic acid cocrystal and its preparation method and application

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129385B2 (en) 2005-04-28 2012-03-06 Shionogi & Co., Ltd. Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SI2320908T1 (en) 2008-07-25 2014-05-30 Viiv Healthcare Company Dolutegravir Prodrugs
CA2744019C (en) * 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
KR101682058B1 (en) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
TWI582097B (en) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 Process for preparing carbamoylpyridone derivatives and intermediates
US20140011995A1 (en) 2010-08-05 2014-01-09 Yukihito Sumino Process for Preparing Compound Having HIV Integrase Inhibitory Activity
EP3016935B1 (en) 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
ZA201503540B (en) 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
TWI677489B (en) 2014-06-20 2019-11-21 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
WO2016092527A1 (en) 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US10975096B2 (en) 2014-06-20 2021-04-13 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives

Also Published As

Publication number Publication date
EP3096763A4 (en) 2017-06-28
ES2770050T3 (en) 2020-06-30
WO2015111080A2 (en) 2015-07-30
US20160333026A1 (en) 2016-11-17
US10301321B2 (en) 2019-05-28
US9856271B2 (en) 2018-01-02
EP3096763A2 (en) 2016-11-30
WO2015110897A3 (en) 2015-12-03
US20180155364A1 (en) 2018-06-07
EP3096763B1 (en) 2019-12-25
WO2015110897A2 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IN2014CH00247A (en)
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
HUE047041T2 (en) Process for the preparation of polyetheramines
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
PH12020550871A1 (en) Process for the preparation of opicapone and intermediates thereof
IN2013MU00646A (en)
JO3487B1 (en) Synthesis of copanlisib and its dihydrochloride salt
IN2013MU00848A (en)
MX2016015464A (en) Oral pharmaceutical composition of isotretinoin.
MX2020009444A (en) Low dose oral pharmaceutical composition of isotretinoin.
EP3099304A4 (en) Novel therapeutics for the treatment of glaucoma
HUE058627T2 (en) New process for the preparation of high purity prostaglandins
IN2013MU03070A (en)
MA40312A (en) Oral pharmaceutical composition of isotretinoin
MA40447A (en) Oral pharmaceutical composition of isotretinoin
IN2014MU01192A (en)
EP3092217A4 (en) A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
IN2013MU01111A (en)
IN2014MU00195A (en)
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX382631B (en) PROCESS FOR THE PREPARATION OF DIHYDROISOXAZOLE DERIVATIVES.
IN2014MU00194A (en)
PL3223799T3 (en) A process for preparation of a drug-polymer composition
MX380240B (en) PREPARATION OF PIPERIDIN-4-CARBOTHIOAMIDE.
IN2014MU01196A (en)